Executive interview – Oryzon

Executive interview – Oryzon

Oryzon Genomics — 8 videos in collection

More on this equity

Oryzon Genomics is a biotech company focused on epigenetics. Iadademstat (Phase IIa) is being explored for acute leukaemias and small-cell lung cancer; Vafidemstat, its CNS product, is in Phase IIa trials in multiple sclerosis, Alzheimer’s disease and aggression. Newer asset ORY-3001 is being developed for certain orphan indications. In this video, the company’s Chief Executive Officer, Carlos Buesa, and Chief Medical Officer Roger Bullock explain the recent R&D progress and expected newsflow.


You may also be interested in these:

Healthcare

Oryzon Genomics – executive interview

Healthcare

Oryzon Genomics – equity proposition

Cookie Policy Overview
Edison Group

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping us understand which section of the website you find more interesting and useful. See our Cookie Policy for more information.

Strictly necessary and functional

These cookies are used to deliver our website and content. Strictly necessary cookies relate to our hosting environment, and functional cookies are used to facilitate social logins, social sharing and rich-media content embeds.

Advertising

Advertising Cookies collect information about your browsing habits such as the pages you visit and links you follow. These audience insights are used to make our website more relevant.

Performance

Performance Cookies collect anonymous information designed to help us improve the site and respond to the needs of our audiences. We use this information to make our site faster, more relevant and improve the navigation for all users.